ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Current Deferred Revenue of $757000.0 for Q1 2026, up 24.3% sequentially from $609000.0 in Q4 2025, and up 40.19% YoY from $540000.0 in Q1 2025.
ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Current Deferred Revenue for 7 years, with the latest figure at $757000.0 in Q1 2026.
- Quarterly Current Deferred Revenue rose 40.19% year-over-year to $757000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $757000.0 (up 40.19% YoY) and the FY2025 annual result came in at $609000.0, up 9.34% from the prior year.
- Current Deferred Revenue improved to $757000.0 in Q1 2026 per SPRY's latest filing, from $609000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.1 million in Q4 2023 and troughed at $10000.0 in Q1 2023.
- A 5-year average of $792000.0 and a median of $557000.0 in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue soared 995.41% in 2023, then tumbled 82.03% in 2024.
- Over 5 years, Current Deferred Revenue stood at $283000.0 in 2022, then jumped by 995.41% to $3.1 million in 2023, then sank by 82.03% to $557000.0 in 2024, then advanced by 9.34% to $609000.0 in 2025, then grew by 24.3% to $757000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $757000.0, $609000.0, and $526000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 535,000.00 |
| Mar 31, 2026 | 757,000.00 |
| Dec 31, 2025 | 609,000.00 |
| Sep 30, 2025 | 526,000.00 |
| Jun 30, 2025 | 746,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Dec 31, 2024 | 557,000.00 |
| Dec 31, 2023 | 3.10 Mn |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | 283,000.00 |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2020 | 3.10 Mn |